Southeast Asian patients with chronic hepatitis C: The impact of novel genotypes and race on treatment outcome

Hepatology

Volumn 36, Issue 5, 2002, Pages 1259-1265

  Dev, Anouk T ^a   McCaw, Rhonda ^b   Sundararajan, Vijaya ^c   Bowden, Scott ^b   Sievert, William ^a  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; REBETRON; RIBAVIRIN;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CAUCASIAN; CHRONIC HEPATITIS; CLINICAL TRIAL; ETHNIC GROUP; EVALUATION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOUTHEAST ASIA; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS TYPING;

EID: 0036829499     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36781     Document Type: Article

References (42)

1. Di Bisceglie AM. Hepatitis C. Lancet 1998;351:331-335.
2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
3. Lau DY-T, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. Ten-year follow up after interferon therapy for chronic hepatitis C. Hepatology 1998;28:1121-1127.
4. WHO 1999. Hepatitis C - Global prevalence (update). Wkly Epidemiol Rec 1999;49:425-427.
5. Khan M, Farrell G, Byth K, Lin R, Weltman M, George J, Samarasinghe D, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513-520.
6. McHutchison JG, Gordon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: Results of a U.S. multi-center randomized controlled trial. N Engl J Med 1998;339:1485-1492.
7. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
8. Davis G, Lau J. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(suppl 1):122S-127S.
9. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
10. Rajender Reddy K, Hoofnagle J, Tong M, Lee W, Pockros P, Heathcote J Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-793.
11. McHutchison J, Poynard T, Pianko S, Gordon S, Reid A, Dienstag J, Morgan T, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-1323.
12. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.
13. Tokita H, Okamoto H, Tsuda F, Song P, Nakata S, Chosa T, lizuka H, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A 1994;91:11022-11026.
14. Mizokami M, Gojobori T, Ohba K, Ikeo K, Ge XM, Ohno T, Orito E, et al. Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes. J Hepatol 1996;24:622-624.
15. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
16. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-2256.
17. Bukh J, Purcell R, Miller R. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 1994;91:8239-8243.
18. Ishak KG, Baptista A, Bianchi L, Callea F, de Groot J, Gudat F, Denk H, et al. Histological grading and sraging of clinical hepatitis. J Hepatol 1995;22:696-699.
19. McCaw R, Moaven L, Locarnini SA, Bowden DS. Hepatitis C virus genotypes in Australia. J Viral Hepat 1997;4:351-357.
20. Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993;159:237-241.
21. Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates. Proc Natl Acad Sci U S A 1991;88:10292-10296.
22. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
23. Enonmoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism. J Gen Virol 1994;75:1361-1369.
24. Enomoto E, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, et al. Comparisons of full length sequences of interferon-sensitinve and resistant hepatitis C virus 1b. Sensitivity is conferred by amino acid substitution in the NS5A region. J Clin Invest 1995;96:224-230.
25. Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, et al. Age-related response to interferon alfa treatment in women vs. men with chronic hepatitis C virus infection. Arch Intern Med 1998;158:177-181.
26. Koskiniemi S, Ebeling F, Farkkila M, Vuoristo M, Nuutinen H, Leino R, Karvonen A-L, et al. HLA-DR alleles predictive for nonresponsiveness to interferon α treatment in chronic hepatitis C infection. Hepatology 1998;28(Part 2):210A.
27. Thursz MR, Yallop R, Mantafounis D, Trepo C, Thomas HC. MHC class II and the outcomes of HCV infection. J Hepatol 1998;28(Suppl 1):95.
28. LasarteJ-J, Garcia-Granero M, Lopez A, Casares N, Garcia N, Civeira M, Borrás-Cuesta F, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998;28:815-822.
29. Nelson DR, Maroysis CG, Ohno T, Davis GL, Lau JYN. Intrahepatic hepatitis C virus specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998;28:225-230.
30. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998;28:1117-1120.
31. Hattori M, Yoshioka K, Aiyama T, Iwata K, Terazawa Y, Ishigami M, Yano M, et al. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: Relation to viral loads and response to interferon. Hepatology 1998;27:1703-1710.
32. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34:1006-1011.
33. Tokita H, Okamoto H, Iizuka H, Tsuda F, Kishimoto J, Miyakawa Y, Mayumi M. The entire nucleotide sequence of three hepatitis C virus isolates in genetic groups 7-9 and comparison with those in the other eight genetic groups. J Gen Virol 1998;79:1847-1857.
34. Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000;95:740-747.
35. Rosen HR, Chou S, Sasaki AW, Gretch DR. Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: Evidence for decreasing relative prevalence of genotype lb. Am J Gastroenrerol 1999;94:3015-3019.
36. Mellor J, Walsh, E, Prescott L, Jarvis L, Davidson F, Yap P, Simmonds P. Survey of type 6 variants of hepatitis C virus in south-east Asia by using core based genotyping assay. J Clin Microbiol 1996;34:417-423.
37. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
38. Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, et al. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 2001;48:830-835.
39. Murashima S, Ide T, Miyajima I, Kumashiro R, Ueno T, Sakisaka S, Sata M. Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Scand J Infect Dis 1999;31:27-32.
40. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O'Brien SJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001;184:16-21.
41. Korenaga M, Hino K, Okita K. A possible role of human leukocyte antigen (HLA) typing for predicting response to interferon therapy in chronic hepatitis C. Nippon Rinsho 2001;59:1345-1350.
42. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001;65:510-516.